Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53-SLP vaccine and cyclophosphamide in ovarian cancer
NCT00844506Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2008
- Primary completion
- Jul 2009
- Countries
- 1
01
Overview
Phase 2, open-label trial of p53 synthetic long peptide vaccine in ovarian cancer, sponsored by University Medical Center Groningen. Started Oct 2008; status: completed.
02
Drugs
p53 synthetic long peptide vaccine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00844506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00844506.